Saturday 17 October 2026 Export SINT’s income statement to Excel — free account

SINTX TECHNOLOGIES, INC.

SINTX TECHNOLOGIES, INC.’s revenue for fiscal 2025 (year ended December 2025) was $1.0 million, down 64.7% from fiscal 2024. In the quarter to June 2026, revenue grew 199.3%, EPS grew 17.6%, free cash flow fell 38.6% and total debt fell 6.42%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

1.74 0.03 −1.69%

Follow SINT

Alert me

Market cap: $13.4M
P/E: 0.0×
Fwd P/E: −1.0×
Dividend yield: —
F-score: 2/9
Altman Z: −45.42
Beneish M: −3.03
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.36

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	1	2	—	3	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 13.38

Revenue 1.33

Net Income (11.28)

Free Cash Flow (10.34)

Net Debt (3.49)

Current Ratio 2.36

Debt/Equity 0.02

P/E ratio 0.00

Fwd P/E (0.95)

P/S ratio 6.34

P/B ratio 1.75

Past 5Y EPS Growth —

This Y EPS Growth 70.29%

Next Y EPS Growth 40.98%

Next Y revenue growth 217.19%

Next 5Y EPS Growth 54.77%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 40.46%

10-year low 10-year high

P/B against its own 10 years 61.00%

10-year low 10-year high

EV/Sales against its own 10 years 22.28%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2026	Powerpack
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	3	4	4	4
Receivables	1	0	0	0
Inventory	1	1	1	2
Other	0	0	—	—
	6	5	6	7

	2023	2024	2025	Q'26
Payables	1	0	0	1
ST’ Debt	0	0	0	0
Other	0	0	3	0
	3	2	4	3

Compound Annual Growth %

	10y	5y	3y
Sales	(26.71%)	11.38%	(13.28%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(14.62%)	(35.28%)	(19.92%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	0	0	—	—	—
’25	0	0	0	0	1
’24	1	1	1	1	3
’23	1	1	1	1	3
’22	0	0	0	1	2
’21	0	0	0	0	1
’20	0	0	0	0	1

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(2)	(3)	—	—	—
’25	(1)	(2)	(3)	(2)	(9)
’24	(3)	(2)	(3)	(1)	(9)
’23	(5)	(3)	(3)	(3)	(14)
’22	(3)	(3)	(2)	(2)	(10)
’21	(3)	(2)	(2)	(2)	(10)
’20	(3)	(2)	(2)	(2)	(9)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(2)	(3)	—	—	—
’25	(1)	(2)	(3)	(2)	(8)
’24	(3)	(3)	(3)	(1)	(9)
’23	(5)	(3)	(3)	(3)	(15)
’22	(3)	(3)	(3)	(2)	(12)
’21	(3)	(3)	(5)	(3)	(14)
’20	(3)	(2)	(2)	(2)	(9)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.70)	(0.75)	—	—	—
’25	(1.29)	(0.91)	(3.46)	(0.34)	(6.16)
’24	(5.14)	(3.61)	(6.95)	0.45	(15.19)
’23	(22.91)	(110.67)	(162.00)	(100.49)	(379.10)
’22	(2.40k)	(2.00k)	(2.17k)	(1.11k)	(7.59k)
’21	(2.13k)	(1.80k)	(1.87k)	(1.64k)	(7.43k)
’20	(30.60k)	(7.00k)	(2.20k)	(2.18k)	(8.06k)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	4,320,000.00	1,734,000.00	96,000.00	25,000.00	5,600.00	11,700.00	1,292.00	67.00	2.01	1.71	Analyst estimates 2026–2028 Powerpack
	High	26,064,000.00	5,320,800.00	2,472,000.00	209,400.00	66,000.00	68,800.00	14,400.00	2,428.00	85.20	7.36
People
People	Employees	35	33	19	28	32	36	41	43	20	32
	Revenue/emp, $m	0.44	0.00	0.01	0.02	0.02	0.02	0.04	0.06	0.14	0.03
Income, $m
Income, $m	Revenue	15	—	0	1	1	1	2	3	3	1
	Gross margin, %	75.19	0.00	41.05	20.03	20.03	25.91	83.02	70.16	71.91	45.28
	EBT	(15)	(6)	(10)	(5)	(7)	(9)	(12)	(8)	(11)	(10)
	EBT margin, %	(96.96)	0.00	(10,198.95)	(696.23)	(1,183.33)	(1,536.14)	(771.24)	(314.39)	(381.85)	(1,018.07)
	Net income	(15)	(6)	(10)	(5)	(7)	(9)	(12)	(8)	(11)	(10)
	Depreciation	2	0	0	0	0	1	1	2	1	1
Per share, $
Per share, $	Revenue	9.86	0.00	0.00	6,890.00	742.50	505.00	1,040.67	140.48	3.89	0.37
	Earnings	(8,868,412.00)	(1,879,880.00)	(1,237,237.00)	(61,600.00)	(7,020.60)	(7,105.40)	(7,502.80)	(444.00)	(14.87)	(6.16)
	Cash flow	(4.64)	(1.57)	0.00	(64,350.00)	(11,390.00)	(8,439.17)	(6,842.00)	(754.81)	(11.66)	(3.09)
	Capex	(0.40)	0.00	0.00	(1,470.00)	(450.00)	(3,000.00)	(936.00)	(26.79)	(0.90)	0.06
	Free cash flow	(5.04)	(1.57)	0.00	(65,820.00)	(11,840.00)	(11,439.17)	(7,778.00)	(781.60)	(12.56)	(3.03)
	Book value	7.28	1.83	0.00	52,020.00	32,255.00	14,329.17	3,802.67	469.09	5.25	1.06
	Shares, m	2	3	0	0	0	0	0	0	1	3
Valuation, ×
Valuation, ×	P/E	0.00	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	472,387.34	—	0.00	4.33	42.29	25.43	1.85	0.55	0.90	10.52
	P/B	640,193.11	—	0.00	0.57	0.97	0.90	0.50	0.17	0.67	3.66
	EV/Sales	472,387.35	—	(0.41)	1.76	0.28	5.84	(1.82)	(0.70)	(0.33)	6.47
	EV/FCF	(923,663.76)	—	0.59	(0.19)	(0.02)	(0.26)	0.24	0.13	0.10	(0.78)
Cash, $m
Cash, $m	Operating cash flow	(7)	(5)	(9)	(6)	(9)	(10)	(10)	(14)	(9)	(9)
	Capex	(1)	0	0	0	0	(4)	(1)	(1)	(1)	0
	Free cash flow	(8)	(5)	(9)	(7)	(9)	(14)	(12)	(15)	(9)	(8)
Balance, $m
Balance, $m	Working capital	2	(5)	5	2	25	12	(1)	3	3	2
	Total debt	7	1	0	0	0	2	1	0	0	0
	Net debt	0	0	(5)	(2)	(25)	(12)	(6)	(3)	(4)	(4)
	Shareholders’ equity	11	5	8	5	26	17	6	9	4	3
Returns, %
Returns, %	ROA	(67.74)	(45.62)	(172.44)	(72.60)	(83.82)	(35.61)	(87.68)	(53.21)	(88.98)	(180.59)
	ROIC	(63.62)	(84.93)	(262.66)	(120.05)	(626.03)	(124.55)	0.00	(152.41)	(2,676.64)	0.00
	ROE	(165.24)	(111.88)	(325.87)	(110.29)	(107.04)	(43.30)	(144.02)	(114.47)	(174.07)	(500.75)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
LFWD Lifeward Ltd.	$17.2M	— (loss-making)	— (loss-making)	+15.71% (above 0%: growing)	n/m	−52.77% (below 0%: shrinking)	40.90%	(62.69%)	Compare
ALUR Allurion Technologies, Inc.	$16.7M	— (loss-making)	— (loss-making)	−47.19% (below 0%: shrinking)	n/m	+65.98% (above 0%: growing)	41.70%	(126.60%)	Compare
HSCS HeartSciences Inc.	$15.4M	— (loss-making)	— (loss-making)	−46.15% (below 0%: shrinking)	n/m	+18.18% (above 0%: growing)	61.90%	(139,957.14%)	Compare
IRIX IRIDEX Corporation	$14.5M	— (loss-making)	— (loss-making)	−7.41% (below 0%: shrinking)	n/m	+130.24% (above 0%: growing)	34.19%	(8.19%)	Compare
RBOT Vicarious Surgical Inc.	$14.3M	— (loss-making)	—	—	n/m	+47.33% (above 0%: growing)	0.00%	0.00%	Compare
SINT SINTX TECHNOLOGIES, INC.	$13.4M	— (loss-making)	— (loss-making)	+199.34% (above 0%: growing)	n/m	−38.60% (below 0%: shrinking)	61.50%	(638.94%)
PETV PetVivo Holdings, Inc.	$12.9M	— (loss-making)	— (loss-making)	+13.48% (above 0%: growing)	n/m	+40.13% (above 0%: growing)	66.14%	(476.54%)	Compare
BTCY Biotricity Inc.	$10.9M	— (loss-making)	— (loss-making)	+10.40% (above 0%: growing)	n/m	+235.83% (above 0%: growing)	82.55%	3.70%	Compare
CTSO Cytosorbents Corporation	$9.7M	— (loss-making)	— (loss-making)	+0.17% (above 0%: growing)	n/m	+64.90% (above 0%: growing)	73.18%	(27.39%)	Compare
Median of peers	$14.4M	—	—	+0.17%	—	+56.12%	51.80%	(45.04%)

All 149 Medical Devices stocks →